help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ØJ, J. A.
Right arrow Articles by BISGAARD, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ØJ, J. A.
Right arrow Articles by BISGAARD, H.

Am. J. Respir. Crit. Care Med., Volume 162, Number 5, November 2000, 1819-1822

Lung Deposition of Inhaled Drugs Increases with Age

JACOB ANH ØJ, LARS THORSSON, and HANS BISGAARD

Department of Paediatrics, Rigshospitalet; Copenhagen University Hospital, Copenhagen, Denmark; and AstraZeneca R&D Lund; and Experimental Medicine, Lund, Sweden

Budesonide plasma concentrations after inhalation of a fixed dose of the drug from a pressurized metered dose inhaler (pMDI) with spacer (Nebuchamber) were compared in young children and adults: 26 patients with mild asthma comprising 8 children 2-3 yr, 8 children 4-6 yr, and 10 adults 20-41 yr. Budesonide 2 × 200 µg was given by pMDI via Nebuchamber with mouthpiece and noseclip. Children of 2-3 yr used a facemask. Plasma was collected regularly for 8 h after drug administration. Budesonide was measured by liquid chromatography plus tandem mass spectrometry. The dose to patient was estimated as the dose of budesonide delivered from the pMDI with adapter minus the amount of budesonide recovered from the spacer, facemask, or mouthpiece, mouth rinse, and facial skin. The systemic exposure was estimated from the plasma concentration and expressed as the area under the curve of plasma concentration versus time (AUC). Terminal half-life (T1/2) was evaluated. Dose to patient, AUC, and T1/2 were similar in the three age groups (p > 0.35). Nebuchamber delivers the same dose of budesonide to young children and adults. Yet the plasma concentration of budesonide was similar in young children and adults. Therefore, lung dose is increased with age. This suggests that from a safety perspective, the prescribed dose of budesonide inhaled from a pMDI with Nebuchamber spacer need not be adjusted for age or use of facemask. Children and adults can use the same nominal dose of budesonide via Nebuchamber as adults without an increased risk of systemic exposure.




This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
A. Tronde, M. Gillen, L. Borgstrom, J. Lotvall, and J. Ankerst
Pharmacokinetics of Budesonide and Formoterol Administered Via 1 Pressurized Metered-Dose Inhaler in Patients With Asthma and COPD
J. Clin. Pharmacol., November 1, 2008; 48(11): 1300 - 1308.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. Loland and H. Bisgaard
Feasibility of Repetitive Lung Function Measurements by Raised Volume Rapid Thoracoabdominal Compression During Methacholine Challenge in Young Infants
Chest, January 1, 2008; 133(1): 115 - 122.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
A. Becker, C. Lemiere, D. Berube, L.-P. Boulet, F. M. Ducharme, M. FitzGerald, T. Kovesi, and on behalf of The Asthma Guidelines Working Group o
Summary of recommendations from the Canadian Asthma Consensus Guidelines, 2003
Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S3 - S11.
[Full Text] [PDF]

Home page
 CMAJHome page
Inhalation devices
Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S39 - S45.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
W. K. Kraft, B. Steiger, D. Beussink, J. N. Quiring, N. Fitzgerald, H. E. Greenberg, and S. A. Waldman
The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers
J. Clin. Pharmacol., January 1, 2004; 44(1): 67 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L. Agertoft and S. Pedersen
Lung Deposition and Systemic Availability of Fluticasone Diskus and Budesonide Turbuhaler in Children
Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 779 - 782.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
G Russell
Inhaled corticosteroids and adrenal insufficiency
Arch. Dis. Child., December 1, 2002; 87(6): 455 - 456.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1581 - 1594.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. PEDERSEN
Do Inhaled Corticosteroids Inhibit Growth in Children?
Am. J. Respir. Crit. Care Med., August 15, 2001; 164(4): 521 - 535.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
I. Amirav, M. T. Newhouse, H. Bisgaard, J. Anhoi, and L. Thorsson
LUNG DEPOSITION OF INHALED DRUGS INCREASES WITH AGE?
Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1279 - 1279.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  CCM abstracts